1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Novaremed AG

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2017

Location

Basel Switzerland

Primary Industry

Biotechnology

About

Based in Basel, Switzerland and founded in 2017, Novaremed AG operates as a biopharmaceutical company that develops small molecules (NRD.E1) to treat patients with diabetic and neuropathic pain. The company was founded by Eli Kaplan. In September 2020, Movaremed raised CHF 2.5 million (USD 2.8 million) in venture funding from unspecified investors. In December 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to NRD.E1 for the treatment of PDPN. The company develops NRD135S.E1 or NRD.E1, an investigational non-opioid small molecule drug for the treatment of Painful Diabetic Neuropathic Pain.
Current Investors
Global Emerging Markets

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.novaremed.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo